Proteomic strategies in the search for novel pancreatic cancer biomarkers and drug targets: recent advances and clinical impact. (2nd April 2016)

• Record Type: Journal Article
• Authors: Coleman, Orla; Henry, Michael; McVey, Gerard; Clynes, Martin; Moriarty, Michael; Meleady, Paula
• Is Part Of: Expert review of proteomics. Volume 13:Number 4(2016)
• Page Start: 383
• Page End: 394
• Publication Date: 2016-04-02
• Subjects: Pancreatic cancer -- proteomics -- diagnosis -- biomarkers -- drug targets -- treatment; Proteins -- Biotechnology -- Periodicals; Proteomics -- Periodicals; 572.6
• DOI: 10.1586/14789450.2016.1167601
• Languages: English
• ISSNs: 1478-9450

Abstract

ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers; despite a low incidence rate it is the fourth leading cause of cancer-related death in the world. Improvement of the diagnosis, prognosis and treatment remains the main focus of pancreatic cancer research. Rapid developments in proteomic technologies has improved our understanding of the pancreatic cancer proteome. Here, the authors summarise the recent proteomic strategies undertaken in the search for: novel biomarkers for early diagnosis, pancreatic cancer-specific proteins which may be used for novel targeted therapies and proteins which may be useful for monitoring disease progression post-therapy. Recent advances and findings discussed here provide great promise of having a significant clinical impact and improving the outcome of patients with this malignancy.